WCN26-4483 Efficacy and safety of remission-induction therapy in patients aged 75 years or older with anti-neutrophil cytoplasmic antibody-associated vasculitis

Read full text Summarise with VIRAT
Authors: Yuma Kawai, Wataru Sone, Takuya Suda, Shouhei Makiishi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Remission induction therapy (RIT) with cyclophosphamide or rituximab is recommended as the standard treatment for anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). However, evidence regarding its efficacy and safety in elderly patients remains limited. This study aimed to evaluate the outcomes of RIT in patients aged 75 years or older with AAV.

Fields of Study & Subjects

Vasculitis and related conditions Renal Diseases and Glomerulopathies Systemic Lupus Erythematosus Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106229–106229
Publication date
25 March 2026
Language
EN